- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 910 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
| BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
| 12.03.25 | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 762 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
| 12.03.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 801 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
| 06.02.25 | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 1.093 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 3,800 | -7,43 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,701 | -9,18 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| ANAVEX LIFE SCIENCES | 3,690 | -0,54 % | Anavex Life Sciences Corp.: Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 | ||
| VERACYTE | 32,800 | +2,50 % | Cathie Wood's weekly recap: ramps up bets on JOBY, CRSP, pares ILMN, VCYT | ||
| ASCLETIS PHARMA | 1,470 | +8,09 % | Sagimet Biosciences Inc.: Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne | SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen | |
| BIOMEA FUSION | 1,060 | -4,07 % | Biomea Fusion, Inc.: Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations |
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications... ► Artikel lesen | |
| JASPER THERAPEUTICS | 1,340 | -6,29 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria | 67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open... ► Artikel lesen | |
| ABSCI | 2,835 | -8,55 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| LANTERN PHARMA | 2,950 | -2,32 % | Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows | NEW YORK, NY / ACCESS Newswire / November 7, 2025 / New to The Street, one of America's leading business television and multi-platform media brands, today announced a comprehensive media partnership... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,610 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| QIAGEN | 43,845 | -0,43 % | QIAGEN N.V.: QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 | QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features QIAGEN... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,79 | -0,19 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| LIMINATUS PHARMA | 1,140 | +5,56 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| BIONTECH | 92,40 | +0,98 % | BioNTech ernennt Kylie Jimenez zur Chief People Officer | Der Aufsichtsrat der BioNTech SE hat Kylie Jimenez mit Wirkung zum 1. März 2026 zur neuen Chief People Officer (Chief People Officer) ernannt. Die neu geschaffene Vorstandsposition umfasst die Verantwortung... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,11 | -1,37 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen |
Das Unternehmen BENEVOLENTAI kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,087 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.